《鮑溫病的治療指南》內(nèi)容預(yù)覽

These guidelines have been prepared for dermatologists onbehalf of the British Association of Dermatologists (BAD) andare based on the best data available at the time the report wasprepared. Caution should be exercised when interpreting datawhere there is a limited evidence base; the results of futurestudies may require alteration of the conclusions or recom-mendations in this report. It may be necessary or even desir-able to depart from the guidelines in the interests of specificpatients and special circumstances. Just as adherence to guide-lines may not constitute defence against a claim of negligence,so deviation from them should not necessarily be deemednegligent.
The scope, aims and methodology of the BAD guidelines pro-cess have been published elsewhere;1,2these references shouldbe consulted for guideline validation purposes.
This article represents a planned regular updating of theprevious BAD guidelines for management of Bowen’s disease(BD).3Those guidelines included discussion of epidemiology,predisposing factors, disease associations and risk of malig-nancy as well as the local treatment options for the diseaseitself. New information in these areas, other than that pertain-ing to issues that influence therapeutic decisions, will only bebriefly summarized in this update. Similarly, detailed evidencefor therapies discussed in the previous paper will not berepeated except where comparison with other evidence isnecessary. It should be recognized that this may entail a dis-proportionate weight being given to referencing newer ther-apies. Where there are direct comparisons between therapies,these are generally discussed in the section relating to thosedeemed to be most efficacious. Recommendations take intoaccount simplicity, cost and healing as well as the type andvalidity of the published evidence base; for any treatment,there may be site-specific differences in the recommendedoption. The abbreviation RCT is used for randomized con-trolled trial throughout.

點(diǎn)擊下載完整版《鮑溫病的治療指南》